The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
Open accessAbstract
CONTEXT: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial. OBJECTIVE: To determine the efficacy, safety, and tolerability of tarenflurbil. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was permitted. INTERVENTION: Tarenflurbil, 800 mg, or placebo, administered twice a day. MAIN OUTCOME MEASURES: Co-primary efficacy end points were the change from baseline to month 18 in total score on the subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, 80-point version) and Alzheimer Disease Cooperative Studies-activities of daily living (ADCS-ADL) scale. Additional prespecified slope analyses explored the possibility of disease modification. RESULTS: Of the 1684 participants randomized, 1649 were included in the analysis, and 1046 completed the trial. Tarenflurbil had no beneficial effect on the co-primary outcomes (difference in change from baseline to month 18 vs placebo, based on least squares means: 0.1 for ADAS-Cog; 95% CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-treat analysis. No significant differences occurred in the secondary outcomes. The ADAS-Cog score decreased by 7.1 points over 18 months. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. CONCLUSION: Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00105547.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite promising preclinical data, unfortunately a phase 3 clinical trial did not demonstrate any benefits on cognition or ADLs over the course of 18 months (Green et al., 2009).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Green et al., 2009
In the citing paper
“A drug intended to modify γ secretase activity similarly failed [256].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [256]
In the citing paper
“Gintonin, a bioactive glycoprotein reduces the formation of A 𝛽, improves learning and memory capacity through the activation of phosphatidic acid receptors involved in hemolysis [26 , 27] .”
From Phytotherapy: A promising approach for the treatment of Alzheimer's disease (2022) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,851
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,006
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Cited by
Sorted by citations
Items 401–500 of 658
Durand, D., Olivera, E., Sáez, A., Carniglia, L., Caruso, C. M., & Lasaga, M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.360273 · Cited by 14
Translational Research in Neurology
Honig, L. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2883 · Cited by 13
Henley, D. B., Sundell, K. L., Sethuraman, G., & Siemers, E. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2413 · Cited by 13
From Neurodegeneration to Brain Health: An Integrated Approach
Petersen, R. B., Lissemore, F. M., Appleby, B. S., Aggarwal, N. T., Boyatzis, R. E., Casadesús, G., Cummings, J., Jack, A. I., Perry, G. L., Safar, J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150043 · Cited by 13
Emerging structures and dynamic mechanisms of γ-secretase for Alzheimer’s disease
Miao, Y., & Wolfe, M. S. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01781 · Cited by 12
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
Loeffler, D. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240212 · Cited by 12
Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C., & Salomone, S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990141 · Cited by 12
TNF and Leptin Tell Essentially the Same Story in Alzheimer's Disease
Clark, I. A., Alleva, L. M., & Vissel, B. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110266 · Cited by 12
Hachuła, B. (2017) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2017.07.005 · Cited by 12
Onaolapo, O. J., Olofinnade, A. T., Ojo, F. O., & Onaolapo, A. Y. (2021) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523021666220815151559 · Cited by 12
Bapineuzumab in Alzheimer's disease: where now?
Wilcock, G. K. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70359-x · Cited by 12
Are We Prepared to Deal With the Alzheimer's Disease Pandemic?
Holtzman, J. L. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.84 · Cited by 12
Li, J., Ma, X., Wang, Y., Chen, C., Hu, M., Wang, L., Fu, J., Shi, G., Zhang, D., & Zhang, T. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00085 · Cited by 12
Drug Treatments in Development for Alzheimer's Disease
Woodward, M. C. (2012) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2012.tb00133.x · Cited by 12
Ultra-Early Phase pathologies of Alzheimer’s disease and other neurodegenerative diseases
Okazawa, H. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.022 · Cited by 12
Jiao, H., Ge, Y., Huang, L.-Y., Liu, Y., Wu, B., Lian, P., Hao, Y., Han, S., Li, Y., Wu, K., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00887-0 · Cited by 11
SAR studies of acidic dual γ-secretase/PPARγ modulators
Hieke, M., Neß, J., Steri, R., Greiner, C., Werz, O., Schubert‐Zsilavecz, M., Weggen, S., & Zettl, H. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.003 · Cited by 11
Biometals and Alzheimer’s Disease
Mot, A. I., & Crouch, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00001-4 · Cited by 11
Alzheimer’s disease: More than amyloid
Chew, S. H., Tomic, M. M. (., & Cheung, A. (2010) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-2010-1356 · Cited by 11
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 11
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10
Stereoselective Synthesis of Selenium-Containing Glycoconjugates via the Mitsunobu Reaction
Serpico, L., Nisco, M. D., Cermola, F., Manfra, M., & Pedatella, S. (2021) · Molecules · doi:10.3390/molecules26092541 · Cited by 10
Hakem, F. T., Fouad, Y. F., & Arafa, R. K. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266259174231006070637 · Cited by 10
Secretase Inhibitors and Modulators as a Disease-Modifying Approach Against Alzheimer's Disease
Gijsen, H. J. M., & Bischoff, F. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00005-9 · Cited by 10
Huang, Y., Li, T., Eatherton, A. J., Mitchell, W. L., Rong, N., Ye, L., Yang, X., Jin, S., Ding, Y., Zhang, J., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.003 · Cited by 10
Disease‐modifying therapy for Alzheimer's disease: Challenges and hopes
Iwata, A., & Iwatsubo, T. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.20 · Cited by 10
Could cholinesterase inhibitors be harmful over the long term?
Schneider, L. S. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211002389 · Cited by 10
γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease
Johnson, D. S., & Pettersson, M. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_19 · Cited by 10
Liu, Y., Cong, L., Han, C., Li, B., & Dai, R. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201127104539 · Cited by 10
The mediterranean diet: Good for the heart = good for the brain?
Barnes, D. E. (2011) · Annals of Neurology · doi:10.1002/ana.22376 · Cited by 10
Zheng, D., Shuai, X., Li, Y., Zhou, P., Gong, T., Sun, X., & Zhang, Z. (2014) · Drug Delivery · doi:10.3109/10717544.2014.954165 · Cited by 10
Jin, M., Xu, R., Alam, M. M., Ma, Z., Zhu, S., Wang, L., Martini, A. C., Bernabucci, M., Xie, P., Kwan, K. Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985173 · Cited by 10
Loeffler, D. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1368200 · Cited by 10
Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00573-1 · Cited by 10
Asthana, A., Tripathi, S., & Agarwal, R. (2024) · Neurology India · doi:10.4103/ni.ni_1073_22 · Cited by 9
Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease
Espay, A. J., Ezzat, K., Kepp, K. P., Daly, T. P., Robakis, N. K. R. K., Meijer, L., & Imbimbo, B. P. (2025) · Brain · doi:10.1093/brain/awaf294 · Cited by 9
Joint space–time Bayesian disease mapping via quantification of disease risk association
Baer, D. R., Lawson, A. B., & Joseph, J. E. (2021) · Statistical Methods in Medical Research · doi:10.1177/0962280220938975 · Cited by 9
Disease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Mitani, Y., Akashiba, H., Saita, K., Yarimizu, J., Uchino, H., Okabe, M., Asai, M., Yamasaki, S., Nozawa, T., Ishikawa, N., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.12.013 · Cited by 9
Cognitive Enhancers in Moderate to Severe Alzheimer's Disease
Hardeland, R. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6344 · Cited by 9
Stäb, J., & Zlatev, I. (2016) · Journal of Nanomedicine & Biotherapeutic Discovery · doi:10.4172/2155-983x.1000140 · Cited by 9
Alzheimer’s disease and its current treatments; Is there a possibility for a cure?
Hathout, R. M., Ammar, E., Mohamed, I., Marel, M., Mohamed, A. S., Nourhan, Z., Abdelbaset, O., Sara, A., Mayar, M., Mirna, M., et al. (2019) · Open Journal of Chemistry · doi:10.17352/ojc.000012 · Cited by 9
Kounnas, M. Z., Durakoglugil, M. S., Herz, J., & Comer, W. T. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.006 · Cited by 9
Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1
Carswell, C. J., Rañopa, M., Pal, S., Macfarlane, R., Siddique, D., Thomas, D. J., Webb, T., Wroe, S. J., Walker, A. S., Darbyshire, J. H., et al. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000339730 · Cited by 9
Effects of External Beam Radiation onIn VitroFormation of Abeta1-42 Fibrils and Preformed Fibrils
Patrias, L. M., Klaver, A. C., Coffey, M. P., Finke, J. M., Digambaranath, J. L., Dang, L., Martinez, A. A., & Loeffler, D. A. (2011) · Radiation Research · doi:10.1667/rr2448.1 · Cited by 9
Shaw, C. A. (2017) · Wiley eBooks · doi:10.1002/9781118634523.refs · Cited by 9
Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
Sil, M., Mukherjee, N., Chatterjee, I., Ghosh, A., & Goswami, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02379-8 · Cited by 9
Laabs, M., Mulac, D., & Langer, K. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107272 · Cited by 8
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Biomarkers for Alzheimer's Disease: Showing the Way or Leading Us Astray?
Quinn, J. F. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129022 · Cited by 8
Clinical Trials and Drug Development
Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100301 · Cited by 8
Li, S., & Bhalla, R. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04178-w · Cited by 8
Flesch, D., Neß, J., Lamers, C., Dehm, F., Popella, S., Steri, R., Ogorek, I., Hieke, M., Dannhardt, G., Werz, O., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.073 · Cited by 7
Strategizing the Development of Alzheimer’s Therapeutics
Davis, J. B., & Couch, R. D. (2014) · Advances in Alzheimer s Disease · doi:10.4236/aad.2014.33011 · Cited by 7
Holtzman, J. L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00059 · Cited by 7
Cunningham, E. L., & Passmore, A. P. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.04.013 · Cited by 7
Drug Development for Alzheimer's Disease: Recent Progress
Ji, W., & Ha, I. (2010) · Experimental Neurobiology · doi:10.5607/en.2010.19.3.120 · Cited by 7
Beyond diagnosis: What biomarkers are teaching us about the “bio”logy of Alzheimer disease
Rabinovici, G. D., & Roberson, E. D. (2010) · Annals of Neurology · doi:10.1002/ana.22020 · Cited by 7
Hierarchical Bayesian cognitive processing models to analyze clinical trial data
Shankle, W. R., Hara, J., Mangrola, T., Hendrix, S. B., Alva, G., & Lee, M. D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.016 · Cited by 7
Chau, S. A., Liu, C. S., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-2414-6_20 · Cited by 7
Membrane anchoring γ-secretase modulators with terpene-derived moieties
Naumann, E. C., Göring, S., Ogorek, I., Weggen, S., & Schmidt, B. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.070 · Cited by 7
Mutual inversion of flurbiprofen enantiomers in various rat and mouse strains
de Bruin, N. M. W. J., Ferreirós, N., Schmidt, M., Hofmann, M. C. J., Angioni, C., Geißlinger, G., & Parnham, M. J. (2018) · Chirality · doi:10.1002/chir.22826 · Cited by 7
Fahimi, A., Noroozi, M., & Salehi, A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819975-6.00011-x · Cited by 6
Asthana, A., Tripathi, S., & Agarwal, R. (2023) · Advances in Alzheimer s Disease · doi:10.4236/aad.2023.121001 · Cited by 6
Historical perspectives on the discovery and development of drugs to treat neurological disorders
Williams, M. J., & COYLE, J. T. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.008 · Cited by 6
Peuchmaur, M., Lacour, M., Sévalle, J., Lisowski, V., Touati‐Jallabe, Y., Rodier, F., Martínez, J., Checler, F., & Hernandez, J. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.045 · Cited by 6
Future Treatment of Alzheimer Disease
Keskin, A. O., Durmaz, N., Uncu, G., Erzurumluoglu, E., Yıldırım, Z., Tuncer, N., & Adapınar, D. Ö. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85096 · Cited by 6
Wobst, I., Ebert, L., Birod, K., Wegner, M.-S., Hoffmann, M., Thomas, D., Angioni, C., Parnham, M. J., Steinhilber, D., Tegeder, I., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010068 · Cited by 6
Metabolic Magnetic Resonance Imaging: A Case for Bioscales in Medicine
Thulborn, K. R., Atkinson, I. C., & Lu, A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0345-7_44 · Cited by 6
Yang, H., Mao, J., Ye, Q., Bucholc, M., Liu, S., Gao, W., Pan, J., Xin, J., & Ding, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1285905 · Cited by 5
ROCKs as a potential drug target to combat Alzheimer's disease
Ahmad, F., Rankawat, S., & Pathak, U. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00012-0 · Cited by 5
Weathered, C., Bardehle, S., Yoon, C., Kumar, N. N., Leyns, C. E. G., Kennedy, M. E., Bloomingdale, P., & Pienaar, E. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13095 · Cited by 6
Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies
Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 6
Medicine’s Valuing of “Normal” Cognitive Ability
Rogers, J. M. G., Hook, C. C., & Havyer, R. D. A. (2015) · The AMA Journal of Ethic · doi:10.1001/journalofethics.2015.17.8.peer1-1508 · Cited by 5
Mécanismes, facteurs de risque et stratégies thérapeutiques dans la maladie d’Alzheimer
Maître, M., Klein, C., & Mensah‐Nyagan, A. G. (2017) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2016.12.006 · Cited by 5
Oxidative Stress in Neurodegenerative Diseases
Alami, M., Fülöp, T., Boumezough, K., Khalil, A., Zerif, E., & Berrougui, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-69962-7_4 · Cited by 6
Lack of enantiomeric influence on the brain cytoprotective effect of ibuprofen and flurbiprofen
López-Villodres, J. A., Cruz, J. P. D. L., Muñoz-Marín, J., Guerrero, A., Reyes, J. J., & Correa, J. A. G. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0661-7 · Cited by 5
Streiner, D. L. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000083 · Cited by 5
Breitner, J. C. S., & Meyer, P. (2020) · Neurology · doi:10.1212/wnl.0000000000009185 · Cited by 5
γ-Secretase fanning the fire of innate immunity
Liu, C., Nikain, C., & Li, Y.-M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221445 · Cited by 4
Efficacy of medications in controlling cognitive dysfunction in Alzheimer’s : a systematic review
de Andrade, S. M., Rodrigues, Í. S. M., Rosa, L. M. V., Taminato, R. L., & dos Santos, G. A. A. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0243 · Cited by 4
The manipulator behind “Scissors”: γ -secretase and its modulators in Alzheimer’s disease
Ning, G., Fan, X., Du, J., wenxue, Z., Sijia, W., Meinei, C., Xiaolong, D., & Yiming, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1637671 · Cited by 5
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 4
New Study Theorizes that Amyloid Beta Protein is an Antimicrobial Peptide
Talan, J. (2010) · Neurology Today · doi:10.1097/01.nt.0000372125.60950.6f · Cited by 4
Clinical neurorestorative progress in Alzheimer’s disease
Qiao, L., Huang, H., & Muresanu, D. F. (2014) · Journal of Neurorestoratology · doi:10.2147/jn.s74143 · Cited by 5
A simple procedure to estimate the optimal sample size in case of conjunctive coprimary endpoints
Varga, Z., Tsang, Y. C., & Singer, J. (2016) · Biometrical Journal · doi:10.1002/bimj.201500231 · Cited by 4
Chau, S. A., Liu, C. S., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2016) · Mental health and illness worldwide · doi:10.1007/978-981-10-0370-7_20-1 · Cited by 5
Alzheimer’s Disease: Treatment Today and Tomorrow
Gorthi, S. P., & Gupta, D. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_254_23 · Cited by 4
Prospects and Challenges for Alzheimer Therapeutics
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00023-x · Cited by 5
Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction
Asakura, K., Evans, S. R., & Hamasaki, T. (2019) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2019.1677494 · Cited by 4
Cao, Y., He, Z., Gao, Y., Xin, Y., Luo, L., & Meng, F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00082 · Cited by 4
Lessons Learned from Major Clinical Trials Conducted Over the Past Decades
Schüler, P., Siegfried, K., & Hüll, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-411464-7.00006-7 · Cited by 4
Neuropathological Basis of Alzheimer’s Disease and Alzheimer’s Disease Diagnosis
Schneider, J. A., Montine, T. J., Sperling, R. A., & Bennett, D. A. (2012) · Advances in biological psychiatry · doi:10.1159/000335384 · Cited by 4
What's New on Alzheimer's Disease? Insights From AD Mouse Models
Rey, C. C., Cattaud, V., Rampon, C., & Verret, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11400-x · Cited by 6
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.
Wang, W. T., Tailor, B. A., Cohen, D. S., & Huang, X. (2019) · PubMed · Cited by 4
Emerging Therapeutic Strategies in Alzheimer's Disease
Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5
New Lessons From the Alzheimer's Disease Neuroimaging Initiative
Salloway, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.344 · Cited by 4
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 3
Modelling of anti-inflammatory treatment in the Alzheimer disease: optimal regimen and outcome
Hajj, W. E., Pujo-Menjouet, L., Tine, L. M., & Volpert, V. A. (2025) · Bulletin of Mathematical Biology · doi:10.1007/s11538-025-01553-8 · Cited by 3
Metadata
- Authors
- Green, R. C.
- Affiliations
- Boston University (US)
- Corresponding author
- Green, Robert C.
- ORCID
- Green, Robert C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-12-16
- Volume
- 302
- Issue
- 23
- Pages
- 2557
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC2902875
- OpenAlex
- W1982816514
- Cited by
- 643
- References
- 44
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 39 · 2023: 22 · 2022: 28 · 2021: 32 · 2020: 43 · 2019: 32 · 2018: 26 · 2017: 40 · 2016: 40 · 2015: 31 · 2014: 44 · 2013: 52 · 2012: 63
- FWCI
- 38.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institute for Health and Care Research
- National Institutes of Health (RR00533, HG02213, AG13846)
- National Institute on Aging (P30AG008051, K24AG027841, P50AG005142, P30AG013846, P30-AG13846))
- National Human Genome Research Institute (R01HG002213, R01 HG02213)
- National Center for Research Resources (M01-RR-00533, M01RR000533)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, mild Alzheimer disease, cognitive decline, activities of daily living, disease modification, ADAS-Cog, drug safety and efficacy, dizziness, anemia, infection
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Cognition Disorders, Double-Blind Method, Enzyme Inhibitors, Female, Flurbiprofen, Humans, Male, Middle Aged, Peptide Fragments, Amyloid beta-Peptides, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
